Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription 10.06.2024 2 Am J Gastroenterol 3 Anticancer Res 4 Biochem Biophys Res Commun 6 BMC Cancer 1 BMC Gastroenterol 11 Clin Res Hepatol Gastroenterol 2 Dig Dis Sci 1 Eur Radiol 3 Gut 1 Hepatology 1 J Clin Oncol 1 J Gastroenterol Hepatol 2 J Hepatol 1 PLoS One 1 Semin Liver Dis 1 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. PAIK JM, Duong S, Zelber-Sagi S, Lazarus JV, et al
   Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction-Associated Fatty Liver Disease Among Adolescents in the United States.
   Am J Gastroenterol. 2024;119:1089-1101.
   PubMed         Abstract available
   
   
2. THABUT D, Rudler M, Weiss N
   Diagnosis of Overt Hepatic Encephalopathy With a New Algorithm: Follow-up Data Are Required.
   Am J Gastroenterol. 2024 Jun 3. doi: 10.14309/ajg.0000000000002856.
   PubMed        
   
   

   
   Anticancer Res

3. FUKUSHIMA NM, Adachi T, Tanaka T, Matsushima H, et al
   DCLK1 Expression and its Functional Significance in Intrahepatic Cholangiocarcinoma and Bil-IN Stage.
   Anticancer Res. 2024;44:2417-2424.
   PubMed         Abstract available
   
   
4. IGARASHI Y, Haruki K, Furukawa K, Taniai T, et al
   Short-term Outcomes of Laparoscopic Versus Open Liver Resection in the Elderly: A Propensity Score-matched Analysis.
   Anticancer Res. 2024;44:2731-2736.
   PubMed         Abstract available
   
   
5. TOREN W, Sasor A, Ansari D, Andersson R, et al
   ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection.
   Anticancer Res. 2024;44:2597-2604.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

6. ZHU J, Liu Q, Nie S, Huang Y, et al
   LEPR/FOS/JUNB signaling pathway contributes to chronic restraint stress-induced tumor proliferation.
   Biochem Biophys Res Commun. 2024;719:150042.
   PubMed         Abstract available
   
   
7. SUN T, Li S, Li X, Lei Y, et al
   Apigenin intervenes in liver fibrosis by regulating PKM2-HIF-1alpha mediated oxidative stress.
   Biochem Biophys Res Commun. 2024;721:150130.
   PubMed         Abstract available
   
   
8. TOMIOKA I, Ota C, Tanahashi Y, Ikegami K, et al
   Loss of the DNA-binding domain of the farnesoid X receptor gene causes severe liver and kidney injuries.
   Biochem Biophys Res Commun. 2024;721:150125.
   PubMed         Abstract available
   
   
9. LI J, Wen W, Li J, Liu T, et al
   CNOT7 regulates lipid deposition in nonalcoholic fatty liver disease.
   Biochem Biophys Res Commun. 2024;721:150003.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. CAO F, Zheng J, Hao W
    Combined image-guided radiofrequency and iodine-125 seeds implantation in the treatment of recurrent hepatocellular carcinoma after hepatectomy.
    BMC Cancer. 2024;24:666.
    PubMed         Abstract available
    
    
11. ZOU W, Fang Z, Feng Y, Gong S, et al
    Transcriptomic and genomic characteristics of intrahepatic metastases of primary liver cancer.
    BMC Cancer. 2024;24:672.
    PubMed         Abstract available
    
    
12. SONG M, Cheng H, Zou H, Ma K, et al
    Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice.
    BMC Cancer. 2024;24:673.
    PubMed         Abstract available
    
    
13. YE J, Ying J, Chen H, Wu Z, et al
    PPIH acts as a potential predictive biomarker for patients with common solid tumors.
    BMC Cancer. 2024;24:681.
    PubMed         Abstract available
    
    
14. ZHU Y, Lu F
    Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1.
    BMC Cancer. 2024;24:682.
    PubMed         Abstract available
    
    
15. ALMOHAID S, Akhtar S
    Diet, lifestyle factors, comorbidities, and hepatocellular carcinoma risk in a middle eastern country: a case-control study.
    BMC Cancer. 2024;24:694.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

16. JAFREE SR, Naveed A, Ahsan H, Burhan SK, et al
    Mental health and quality of life in patients with chronic liver disease: a single-center structural equation model.
    BMC Gastroenterol. 2024;24:193.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

17. L'HUILLIER R, Michoud C, Dumortier J, Milot L, et al
    Massive peritoneal tumoral dissemination after hepatocellular carcinoma percutaneous microwave ablation with intraperitoneal CO(2) insufflation.
    Clin Res Hepatol Gastroenterol. 2024;48:102376.
    PubMed        
    
    
18. ROGALSKI J, Czarnecka-Chrebelska K, Weglewska K, Pleska K, et al
    Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients.
    Clin Res Hepatol Gastroenterol. 2024;48:102366.
    PubMed        
    
    
19. ZHOU J, Liang T, Xing F, Li X, et al
    Probabilistic Scatter Plots for visualizing carbohydrate and lipid metabolism states in Non-Alcoholic Fatty Liver Disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102365.
    PubMed         Abstract available
    
    
20. ZHAO G, Shi R, Ma M, Lin H, et al
    Elevated LDL-c may warn of the risk of gallbladder stones in the patients with metabolic dysfunction-associated steatotic liver disease: A case-control study.
    Clin Res Hepatol Gastroenterol. 2024;48:102363.
    PubMed         Abstract available
    
    
21. MAREY MM, Belal M, Awad AA, Rabea EM, et al
    Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2024;48:102357.
    PubMed         Abstract available
    
    
22. LEIDECK P, Nkontchou G, Elkrief L, Erard D, et al
    The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience.
    Clin Res Hepatol Gastroenterol. 2024;48:102355.
    PubMed         Abstract available
    
    
23. TANAKA A, Corpechot C
    PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old.
    Clin Res Hepatol Gastroenterol. 2024;48:102358.
    PubMed         Abstract available
    
    
24. ZHOU F, Liu X, Chang C, Liu J, et al
    Separating the effects of early and later life body mass index on liver diseases: A Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102352.
    PubMed         Abstract available
    
    
25. BOEKEN T
    Redefining challenging liver thermal ablation cases: Present realities, future prospects.
    Clin Res Hepatol Gastroenterol. 2024;48:102342.
    PubMed        
    
    
26. MENG X, Wang L, Du YC, Cheng D, et al
    PPARbeta/delta as a promising molecular drug target for liver diseases: A focused review.
    Clin Res Hepatol Gastroenterol. 2024;48:102343.
    PubMed         Abstract available
    
    
27. PAN X, Hu E, Zhou Y, Li L, et al
    The prognostic nutritional index as a predictor of efficacy and early recurrence for adjuvant transarterial chemoembolization in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102344.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

28. SHIH HW, Lai Y, Hung HC, Lee JC, et al
    Liver Resection Criteria for Patients with Hepatocellular Carcinoma and Multiple Tumors Based on Total Tumor Volume.
    Dig Dis Sci. 2024 Jun 1. doi: 10.1007/s10620-024-08500.
    PubMed         Abstract available
    
    
29. FULLER SR, Schreiner AD
    Hepatic Fibrosis Risk Assessment in Primary Care: Opportunities and Challenges.
    Dig Dis Sci. 2024 Jun 6. doi: 10.1007/s10620-024-08498.
    PubMed        
    
    

    
    Eur Radiol

30. PICKHARDT PJ, Blake GM, Moeller A, Garrett JW, et al
    Post-contrast CT liver attenuation alone is superior to the liver-spleen difference for identifying moderate hepatic steatosis.
    Eur Radiol. 2024 Jun 4. doi: 10.1007/s00330-024-10816.
    PubMed         Abstract available
    
    

    
    Gut

31. CHEN A, Zhang VX, Zhang Q, Sze KM, et al
    Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.
    Gut. 2024 Jun 5:gutjnl-2024-331903. doi: 10.1136/gutjnl-2024-331903.
    PubMed         Abstract available
    
    
32. NISCHALKE HD, Nischalke C, Schmalz F, Moller C, et al
    Catecholamines and inflammation in advanced liver disease: more closely intertwined than expected?
    Gut. 2024;73:1219-1222.
    PubMed        
    
    
33. BU L, Zhang Z, Chen J, Fan Y, et al
    High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT.
    Gut. 2024;73:1156-1168.
    PubMed         Abstract available
    
    

    
    Hepatology

34. WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
    A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. ETTRICH TJ, Modest DP, Sinn M, Striefler JK, et al
    Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
    J Clin Oncol. 2024 Jun 6:JCO2301566. doi: 10.1200/JCO.23.01566.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

36. WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al
    LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites.
    J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637.
    PubMed         Abstract available
    
    

    
    J Hepatol

37. PATERNOSTRO R, Kwanten WJ, Hofer BS, Semmler G, et al
    Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    J Hepatol. 2024 May 30:S0168-8278(24)00368-4. doi: 10.1016/j.jhep.2024.
    PubMed         Abstract available
    
    
38. LAO Y, Cui X, Xu Z, Yan H, et al
    Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.
    J Hepatol. 2024 May 31:S0168-8278(24)00369-6. doi: 10.1016/j.jhep.2024.
    PubMed         Abstract available
    
    

    
    PLoS One

39. HUANG X, Gu H, Shen P, Zhang X, et al
    Systematic review and meta-analysis: Evaluating the influence of intrahepatic cholestasis of pregnancy on obstetric and neonatal outcomes.
    PLoS One. 2024;19:e0304604.
    PubMed         Abstract available
    
    

    
    Semin Liver Dis

40. LIU H, Sethi V, Li X, Xiao Y, et al
    Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.
    Semin Liver Dis. 2024;44:e1-e3.
    PubMed        
    
    

    
    Transplantation

41. WEHRLE CJ, Kusakabe J, Akabane M, Maspero M, et al
    Expanding Selection Criteria in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Long-term Follow-up of a National Registry and 2 Transplant Centers.
    Transplantation. 2024 Jun 4. doi: 10.1097/TP.0000000000005097.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.